验证数据展示
经过测试的应用
Positive IF/ICC detected in | HeLa cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL488-68315 targets EXOSC10 in IF/ICC applications and shows reactivity with human samples.
经测试应用 | IF/ICC Application Description |
经测试反应性 | human |
免疫原 | EXOSC10 fusion protein Ag28587 种属同源性预测 |
宿主/亚型 | Mouse / IgG1 |
抗体类别 | Monoclonal |
产品类型 | Antibody |
全称 | exosome component 10 |
别名 | RRP6, PM/Scl-100, P100 polymyositis-scleroderma overlap syndrome-associated autoantigen, Exosome complex component 10, EC:3.1.13.- |
计算分子量 | 98 kDa |
观测分子量 | 98 kDa |
GenBank蛋白编号 | BC039901 |
基因名称 | EXOSC10 |
Gene ID (NCBI) | 5394 |
RRID | AB_3672994 |
偶联类型 | CoraLite® Plus 488 Fluorescent Dye |
最大激发/发射波长 | 493 nm / 522 nm |
形式 | Liquid |
纯化方式 | Protein G purification |
UNIPROT ID | Q01780 |
储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
About 50% of patients with polymyositis/scleroderma (PM-Scl) overlap syndrome are reported to have autoantibodies to a neuclear/nucleolar particle termed PM-Scl. Exosome component 10 (EXOSC10), also named autoantigen PM/Scl 2, is the 100 kDa antigen component of PM-Scl and is recognized by most sera of PM-Scl paitents. EXOSC10 is strongly enriched in the nucleolus and a small amount has been found in cytoplasm supporting the existence of a nucleolar RNA exosome complex form. As a putative catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity, EXOSC10 participates in a multitude of cellular RNA processing and degradation events.
实验方案
Product Specific Protocols | |
---|---|
IF protocol for CL Plus 488 EXOSC10 antibody CL488-68315 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |